Atea Pharmaceuticals announced a successful End-of-Phase 2 meeting with the FDA and plans to start patient enrollment for its global Phase 3 program for treating hepatitis C virus (HCV) in April 2025.

People with hepatitis C virus who inject drugs could be evaluated for cure approximately 2 months earlier than current ...

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...

A bipartisan group of lawmakers in the House of Representatives and the Senate have introduced a new bill seeking to expand the U.S. Department of Housing and Urban Development (HUD)’s Housing Choice ...

Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) ...